Bringing hope through science for patients with hard-to-treat cancers
Oncopeptides develops innovative therapies for patients facing some of the most challenging cancers, including multiple myeloma. We combine scientific excellence, entrepreneurial spirit, and a deep commitment to improving patients’ lives, taking science from lab to clinic.
Our story
Multiple myeloma is an incurable blood cancer. Symptoms like bone pain, fatigue, and infections severely reduce quality of life. Despite advances in treatment, most patients eventually relapse and become resistant to all available therapies, creating a critical need for innovative options.
Science
Melflufen is the first treatment of its kind, developed to deliver cancer-killing agents directly inside multiple myeloma cells. It uses enzymes in these cells to activate and release its active substance, damaging cancer DNA and helping to stop disease progression.